Figure 4.

PPARγ mediates rosiglitazone‐induced up‐regulation of ANGPTL4 in HUVECs. HUVECs were treated with rosiglitazone (0, 0.25, 0.5, 1, 10 and100 μM) for 24 h with pre‐treatment of T0070907 (10 μM) or not. (A and B) Effects of rosiglitazone on mRNA levels of PPARγ and ANGPTL4 in HUVECs. (C‐E) Typical bands and statistical results of protein abundance of PPARγ and ANGPTL4 in HUVECs after rosiglitazone treatment. Arrowhead denotes the specific band of ANGPTL4 in HUVECs. (F) Concentrations of ANGPTL4 in culture medium of HUVECs after rosiglitazone treatment. The data are shown as the mean ± SD values of at least three independent experiments performed. *P < .05 and **P < .01 compared with corresponding control